Immediate discontinuation in case of severe hypersensitivity or anaphylactic-type reactions. Shock could develop if accidentally administered into a blood vessel. Risk of adverse reactions is more frequent when receiving human normal Ig for the 1st time or, in rare cases, when switching between human normal Ig products or when there has been long interval since previous infusion. Avoid potential complications by initially injecting the product slowly, then ensuring careful monitoring for any symptoms throughout infusion period. Patients w/ anti-IgA Ab should be treated only under close medical supervision. Patients at risk for thrombosis should receive Cuvitru at the slowest infusion rate practicable & be monitored for thrombotic complications. Reports of severe renal adverse reactions including acute renal failure, acute tubular necrosis, proximal tubular nephropathy, & osmotic nephrosis. Reports of aseptic meningitis syndrome, occurring more frequently in female patients. Monitor patients for hemolysis, particularly those at increased risk. Interference w/ serological testing (eg, misleading or false +ve results). Possible transmission of infectious agents. May impair ability to drive or operate machinery. Balance potential risk & only prescribe to pregnant & breastfeeding women if clearly needed.
Sign Out
